Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 48 Days Sales Outstanding is 95.60 as of Jun. 2026, which is 4% above its 10-year median of 91.52. GuruFocus rates CHIX:BOULS with a GF Score™ of 48/100 and a GF Value™ of kr47.05. The stock has 3 warning signs investors should review. Among 812 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 76.85% on this metric.
The historical rank and industry rank for Boule Diagnostics AB's Days Sales Outstanding or its related term are showing as below:
CHIX:BOULs'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.65 Med: 91.52 Max: 102.47
Current: 96.98
During the past 13 years, Boule Diagnostics AB's highest Days Sales Outstanding was 102.47. The lowest was 67.65. And the median was 91.52.
CHIX:BOULs's Days Sales Outstanding is ranked worse than 76.85% of 812
companies
in the Medical Devices & Instruments industry
Industry Median: 65.165
vs CHIX:BOULs: 96.98
Boule Diagnostics AB's Days Sales Outstanding
increased
from Jun. 2025 (91.43) to Jun. 2026 (95.60).
Boule Diagnostics AB (CHIX:BOULs) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Boule Diagnostics AB Days Sales Outstanding Related Terms
Boule Diagnostics AB Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:BOULS vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Days Sales Outstanding falls into.
Boule Diagnostics AB Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB (CHIX:BOULS) has a Days Sales Outstanding of 95.60 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Boule Diagnostics AB and its competitors. This is near median its historical median of 91.52. Over the past decade, Boule Diagnostics AB's Days Sales Outstanding has ranged from 67.65 to 102.47. According to the industry distribution chart, Boule Diagnostics AB ranks #624 out of 812 companies in the Medical Devices & Instruments industry, placing it in the top 76.8%.
Is Boule Diagnostics AB's Days Sales Outstanding too high?
Boule Diagnostics AB's current Days Sales Outstanding of 95.60 is near median its 10-year median of 91.52. Over the past 10 years, this metric has ranged from a low of 67.65 to a high of 102.47. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.17. Boule Diagnostics AB's value of 95.60 is 46.7% above this industry median. Based on the distribution chart, Boule Diagnostics AB ranks #624 out of 812 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #624 out of 812 companies for Days Sales Outstanding. This places Boule Diagnostics AB in the lower half of its industry. The industry median Days Sales Outstanding is 65.17. Boule Diagnostics AB's value of 95.60 is 46.7% above this benchmark. Historically, Boule Diagnostics AB's own Days Sales Outstanding has ranged from 67.65 to 102.47 over the past decade. While the company's 10-year median is 91.52 vs. the industry median of 65.17, Boule Diagnostics AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.17, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Boule Diagnostics AB's current Days Sales Outstanding of 95.60 is 46.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Days Sales Outstanding is 95.60, which is near median its own 10-year median of 91.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Days Sales Outstanding of 95.60. The stock's GF Value™ is kr47.05, compared to a current price of kr26.30 — trading 44.1% below its estimated fair value. The current Days Sales Outstanding is 95.60, which is near median its 10-year median of 91.52 and 46.7% above the Medical Devices & Instruments industry median of 65.17. Boule Diagnostics AB's overall GF Score™ is 48/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Days Sales Outstanding is 95.60 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 44.1% below its estimated GF Value™ of kr47.05.
Key valuation signals for CHIX:BOULS:
Days Sales Outstanding: 95.60 (near median its 10-year median of 91.52)
GF Value™: kr47.05 vs. price of kr26.30 (44.1% below fair value)
Industry Position: 46.7% above the Medical Devices & Instruments median (#624 of 812)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
48GF Score
Get the complete analysis for CHIX:BOULS
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
